Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives

Leukemia & Lymphoma
R Landolfi, C Patrono

Abstract

The role of aspirin in the antithrombotic strategy of patients with polycythemia vera (PV) and essential thrombocythemia (ET) is highly controversial. Long considered unsafe on the basis of a single clinical trial testing very high doses in PV patients, aspirin is being increasingly used at lower dosage. The rationale for the use of aspirin in patients with PV and ET is provided by the efficacy of this agent in the treatment of microcirculatory disturbances of thrombocythemic states associated with myeloproliferative disorders and by recent evidence that asymptomatic PV and ET patients have persistently increased thromboxane (TX) A2-biosynthesis. This increase, which most likely reflects enhanced platelet activation in vivo, is independent of the platelet mass and blood viscosity and largely supressed by a short term low-dose aspirin regimen (50 mg/day for 7 days). Since enhanced TXA2 biosynthesis may play a role in transducing the increased thrombotic risk associated with PV and ET, long-term low-dose aspirin administration has been proposed as a possible antithombotic strategy in these subjects. The safety of this treatment in PV patients has been recently reassessed by the Gruppo Italiano per lo Studio della Policitemia Vera...Continue Reading

References

Nov 1, 1978·British Journal of Haematology·S BatemanA Zaafran
Dec 1, 1975·Journal of Medical Genetics·J G Hall, H Herrod
Aug 1, 1992·British Journal of Haematology·G Birgegård, L Wide
Feb 11, 1991·The Journal of Clinical Investigation·C H DaiH S Gilbert
Mar 1, 1991·Mayo Clinic Proceedings·J L Diez-MartinG W Dewald
Nov 1, 1990·European Journal of Haematology·L Biljanović-PaunovićV Pavlović-Kentera
Jan 1, 1989·Clinical and Laboratory Haematology·B Zhang, S M Lewis
Apr 1, 1989·European Journal of Haematology·S PartanenT Ruutu
Sep 6, 1986·British Medical Journal·J C Moore-GillonI R Cameron
Apr 1, 1988·European Journal of Haematology·M MessinezyT C Pearson
Jul 31, 1986·The New England Journal of Medicine·P M CotesC Reid
Apr 1, 1987·Cancer Genetics and Cytogenetics·G Rege-CambrinH Van den Berghe
Jan 1, 1973·Scandinavian Journal of Haematology·S W RasmussenM Larsen
Oct 1, 1983·Scandinavian Journal of Haematology·E YuenH Kronenberg
Feb 1, 1980·British Journal of Haematology·C LacombeB Varet
Sep 1, 1994·European Journal of Haematology·M MessinezyT C Pearson
May 1, 1994·Annals of Epidemiology·J Schwartz, S T Weiss
Sep 1, 1993·British Journal of Haematology·R E Gale, J S Wainscoat
Sep 1, 1993·European Journal of Haematology·P ReveszJ Kutti
Jan 1, 1993·European Journal of Haematology·R BartlW Wilmanns
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A de la ChapelleE Juvonen

❮ Previous
Next ❯

Citations

Mar 1, 1997·Blood Reviews·A TefferiM N Silverstein
May 23, 1998·Blood Reviews·S Willoughby, T C Pearson
Apr 14, 1999·Australian and New Zealand Journal of Medicine·A K MillsC Kelly
Oct 6, 2001·The Clinical Journal of Pain·C McCrory, D Westerling
Jan 20, 2000·Baillière's Clinical Haematology·A Tefferi, M N Silverstein
Mar 22, 2000·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·J J Michiels

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.